在贝宁南部，氯喹和磺胺多辛-乙胺嘧啶的治疗效果显著下降，但甲氟喹并非如此。
Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin.
作者信息
Aubouy Agnès, Fievet Nadine, Bertin Gwladys, Sagbo Jean C, Kossou Hortense, Kinde-Gazard Dorothée, Kiniffo Richard, Massougbodji Achille, Deloron Philippe
机构信息
Research Unit 010 (UR010), Mother and Child Health in the Tropics, Development Research Institute (IRD), Cotonou, Benin.
出版信息
Trop Med Int Health. 2007 Jul;12(7):886-94. doi: 10.1111/j.1365-3156.2007.01859.x.
OBJECTIVE
To evaluate the in vivo therapeutic efficacy of chloroquine (CQ), sulfadoxine-pyrimethamine (SP) and mefloquine (MQ) in children presenting with uncomplicated malaria in Benin.
METHODS
Drug efficacy was tested according to the WHO in vivo 28-day protocol. For failures that occurred after 7 days of follow-up, paired pre- and post-treatment blood samples were genotyped at msp1 and msp2 loci to distinguish new infections and recrudescent strains. Children enrolled were randomly assigned to a therapeutic group (CQ, n=14; SP, n=42; MQ, n=44). The number of CQ treatment was intentionally restricted after 1 month, as its use was considered to constitute a danger for children.
RESULTS
Chloroquine and SP showed very high failure rates (85.7% and 50%, respectively), whereas MQ treatment was successful in 97.5%. The molecular tool allowed to re-evaluate two new infections previously considered as failures.
CONCLUSIONS
Chloroquine should no longer be used to treat children presenting with Plasmodium falciparum malaria in Benin.
目的
评估氯喹（CQ）、磺胺多辛-乙胺嘧啶（SP）和甲氟喹（MQ）对贝宁单纯性疟疾患儿的体内治疗效果。
方法
根据世界卫生组织的体内28天方案测试药物疗效。对于随访7天后出现的治疗失败情况，对配对的治疗前和治疗后血样在msp1和msp2基因座进行基因分型，以区分新感染和复发菌株。纳入的儿童被随机分配到治疗组（CQ组，n = 14；SP组，n = 42；MQ组，n = 44）。1个月后有意限制了CQ的治疗例数，因为其使用被认为对儿童构成危险。
结果
氯喹和SP显示出非常高的失败率（分别为85.7%和50%），而MQ治疗的成功率为97.5%。该分子工具能够重新评估两个先前被视为治疗失败的新感染病例。
结论
在贝宁，氯喹不应再用于治疗患恶性疟原虫疟疾的儿童。
Zotero 插件